Abstract
Simulation models from the early COVID-19 pandemic highlighted the urgency of applying non-pharmaceutical interventions (NPIs), but had limited empirical data. Here we use data from 2020-2021 to retrospectively model the impact of NPIs. Our model represents age groups and census divisions in Ontario, Canada, and is parameterised with epidemiological, testing, demographic, travel, and mobility data. The model captures how individuals adopt NPIs in response to reported cases. Combined school/workplace closure and individual NPI adoption reduced the number of deaths in the best-case scenario for the case fatality rate (CFR) from 174, 411 [CI: 168, 022, 180, 644] to 3, 383 [CI: 3, 295, 3, 483] in the Spring 2020 wave. In the Fall 2020/Winter 2021 wave, the introduction of NPIs in workplaces/schools reduced the number of deaths from 17, 291 [CI: 16, 268, 18, 379] to 4, 167 [CI: 4, 117, 4, 217]. Deaths were several times higher in the worst-case CFR scenario. Each additional 7 − 11 (resp. 285 − 452) individuals who adopted NPIs in the first wave prevented one additional infection (resp., death). Our results show that the adoption of NPIs prevented a public health catastrophe.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the Ministry of Colleges and University of Ontario and the NSERC COVID-19 Alliance program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Reformatting/editing for journal submission including some movement of content between main document and supplementary information, various small edits to text.
Data Availability
Data sets required to run simulations are available in a GitHub repository (https://github.com/k3fair/COVID-19-ON-model). Data sets generated from our analysis and simulations are available from the corresponding author upon reasonable request. All epidemiological, testing, demographic, travel, and mobility data used to parametrise the model are publicly available online.